TY - JOUR
T1 - Mapping depression rating scale phenotypes onto research domain criteria (RDoC) to inform biological research in mood disorders
AU - The Mood Disorders Precision Medicine Consortium (MDPMC)
AU - Ahmed, Ahmed T.
AU - Frye, Mark A.
AU - Rush, A. John
AU - Biernacka, Joanna M.
AU - Craighead, W. Edward
AU - McDonald, William M.
AU - Bobo, William V.
AU - Riva-Posse, Patricio
AU - Tye, Susannah J.
AU - Mayberg, Helen S.
AU - Flavin, Daniel Hall
AU - Skime, Michelle K.
AU - Jenkins, Greg D.
AU - Wang, Liewei
AU - Krishnan, Ranga Rama
AU - Weinshilboum, Richard M.
AU - Kaddurah-Daouk, Rima
AU - Dunlop, Boadie W.
N1 - Funding Information:
Emory PReDICT. National Institute of Mental Health Centers for Intervention Development and Applied Research (CIDAR) grant (P50 MH077083; PI: Helen Mayberg, MD) established the center and provided funds to assess participants for predictors of acute response. RO1 MH080880; PI: W Edward Craighead, PhD provided funding to treat non-remitters to the first treatment with combination medication and psychotherapy, to allow follow-up of patients for up to two years to identify predictors of recurrence, and to add patients to the sample to adequately power these studies. Additional support was received from PHS Grant UL1 RR025008 from the Clinical and Translational Science Award program, National Institutes of Health, National Center for Research Resources, PHS Grant M01 RR0039 from the General Clinical Research Center program, and K23 MH086690 (BWD).
Funding Information:
AA is supported by the Mayo Clinic NIH Clinical Pharmacology Training Grant T32 GM008685 . Mayo PGRN-AMPS. This research was supported, in part, by NIH grants RO1 GM28157 , U19 GM61388 (The Pharmacogenomics Research Network).
Funding Information:
Emory PReDICT. National Institute of Mental Health Centers for Intervention Development and Applied Research ( CIDAR ) grant ( P50 MH077083 ; PI: Helen Mayberg, MD) established the center and provided funds to assess participants for predictors of acute response. RO1 MH080880; PI: W Edward Craighead, PhD provided funding to treat non-remitters to the first treatment with combination medication and psychotherapy, to allow follow-up of patients for up to two years to identify predictors of recurrence, and to add patients to the sample to adequately power these studies. Additional support was received from PHS Grant UL1 RR025008 from the Clinical and Translational Science Award program, National Institutes of Health, National Center for Research Resources , PHS Grant M01 RR0039 from the General Clinical Research Center program, and K23 MH086690 (BWD) .
Funding Information:
Emory PReDICT. National Institute of Mental Health Centers for Intervention Development and Applied Research ( CIDAR ) grant ( P50 MH077083 ; PI: Helen Mayberg, MD) established the center and provided funds to assess participants for predictors of acute response. RO1 MH080880 ; PI: W Edward Craighead, PhD provided funding to treat non-remitters to the first treatment with combination medication and psychotherapy, to allow follow-up of patients for up to two years to identify predictors of recurrence, and to add patients to the sample to adequately power these studies. Additional support was received from PHS Grant UL1 RR025008 from the Clinical and Translational Science Award program, National Institutes of Health , National Center for Research Resources , PHS Grant M01 RR0039 from the General Clinical Research Center program, and K23 MH086690 (BWD).
Publisher Copyright:
© 2018 Elsevier B.V.
PY - 2018/10/1
Y1 - 2018/10/1
N2 - Background: Substantial research progress can be achieved if available clinical datasets can be mapped to the National Institute of Mental Health Research-Domain-Criteria (RDoC) constructs. This mapping would allow investigators to both explore more narrowly defined clinical phenotypes and the relationship of these phenotypes to biological markers and clinical outcomes approximating RDoC criteria. Methods: Using expert review and consensus, we defined four major depression phenotypes based on specific RDoC constructs. Having matched these constructs to individual items from the Hamilton Depression Rating Scale and Quick Inventory of Depressive Symptomatology, we identified subjects meeting criteria for each of these phenotypes from two large clinical trials of patients treated for major depression. In a post hoc analysis, we evaluated the overall treatment response based on the phenotypes: Core Depression (CD), Anxiety (ANX), and Neurovegetative Symptoms of Melancholia (NVSM) and Atypical Depression (NVSAD). Results: The phenotypes were prevalent (range 10.5–52.4%, 50% reduction range 51.9–82.9%) and tracked with overall treatment response. Although the CD phenotype was associated with lower rates of remission in both cohorts, this was mainly driven by baseline symptom severity. However, when controlling for baseline severity, patients with the ANX phenotype had a significantly lower rate of remission. Limitations: The lack of replication between the studies of the phenotypes’ treatment prediction value reflects important variability across studies that may limit generalizability. Conclusion: Further work evaluating biological markers associated with these phenotypes is needed for further RDoC concept development.
AB - Background: Substantial research progress can be achieved if available clinical datasets can be mapped to the National Institute of Mental Health Research-Domain-Criteria (RDoC) constructs. This mapping would allow investigators to both explore more narrowly defined clinical phenotypes and the relationship of these phenotypes to biological markers and clinical outcomes approximating RDoC criteria. Methods: Using expert review and consensus, we defined four major depression phenotypes based on specific RDoC constructs. Having matched these constructs to individual items from the Hamilton Depression Rating Scale and Quick Inventory of Depressive Symptomatology, we identified subjects meeting criteria for each of these phenotypes from two large clinical trials of patients treated for major depression. In a post hoc analysis, we evaluated the overall treatment response based on the phenotypes: Core Depression (CD), Anxiety (ANX), and Neurovegetative Symptoms of Melancholia (NVSM) and Atypical Depression (NVSAD). Results: The phenotypes were prevalent (range 10.5–52.4%, 50% reduction range 51.9–82.9%) and tracked with overall treatment response. Although the CD phenotype was associated with lower rates of remission in both cohorts, this was mainly driven by baseline symptom severity. However, when controlling for baseline severity, patients with the ANX phenotype had a significantly lower rate of remission. Limitations: The lack of replication between the studies of the phenotypes’ treatment prediction value reflects important variability across studies that may limit generalizability. Conclusion: Further work evaluating biological markers associated with these phenotypes is needed for further RDoC concept development.
KW - Anxiety
KW - Core depression
KW - Major depressive disorder
KW - Neurovegetative symptoms of melancholia and atypical depression
KW - Research domain criteria
UR - http://www.scopus.com/inward/record.url?scp=85047610520&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85047610520&partnerID=8YFLogxK
U2 - 10.1016/j.jad.2018.05.005
DO - 10.1016/j.jad.2018.05.005
M3 - Article
C2 - 29807322
AN - SCOPUS:85047610520
SN - 0165-0327
VL - 238
SP - 1
EP - 7
JO - Journal of Affective Disorders
JF - Journal of Affective Disorders
ER -